# US 11,307,207 B2 · Method to analyze compounds in biological samples > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,307,207 B2 - Document ID: US11307207B2 - Status: Granted - Kind: B2 - Application number: 16/427,907 - Filed: 2019-05-31 - Published: 2019-10-24 - Granted: 2022-04-19 - Earliest claimed: 2016-12-02 - Assignees: Magtivio B.V. - Applicants: magtivio b.v - Inventors: Mario Wuttke; Viorel Rusu; Erik Ruijters; Gerbert Schaap; Sven Goethel - Web page: https://patentgrep.com/patent/US11307207B2 ## CPC - G01N 33/54326: {Magnetic particles} - G01N 33/6848: {Methods of protein analysis involving mass spectrometry} - B01L 3/502715: {characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces} - B01L 3/502753: {characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation} - G01N 21/64: Fluorescence; Phosphorescence - G01N 33/4833: {of solid biological material, e.g. tissue samples, cell cultures (tissue in vivo A61B5/00; cell suspensions G01N33/48735)} - B01L 2300/069: Absorbents; Gels to retain a fluid - B01L 2300/12: Specific details about materials - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE ## Abstract Various embodiments of the present disclosure relate to a method for analyzing target compounds from a fluid or dried biological sample by using a microfluidic sample device including a hollow cartridge and an absorbent body unit. ## Claims ### Claim 1 A method to analyze target analyte compounds from a fluid biological sample by using a microfluidic sample device comprising a hollow cartridge and an absorbent body unit, the absorbent body unit comprising a filter paper, a capillary pipette tip, or a modified polymeric sintered filter body that is configured to be attached to the hollow cartridge with a pipette-like geometry, the method comprising: a) soaking and storing the fluid biological sample in the absorbent body unit, wherein: the absorbent body unit comprises one or more single layer structures; different functional groups densities of COOH, NH2, OH, TiO2, and/or ZrO2 are present in each of the one or more single layer structures as a binding tool for a pre-cleaning step; a first coating comprising Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), -ethoxyquin, polyacrylic acid (PAA), polyethyleneimine (PEI), sorbitan esters, polyethoxy sorbitan esters octylphenoxypolyethoxyethanol, Na2- EDTA, Na-citrate, and/or hydrogels is present on each of the one or more single layer structures as artificial antioxidants and as active hydrophilic compounds; the absorbent body unit is positioned at a distal end of the hollow cartridge and a proximal end of the hollow cartridge comprises a passage that is configured to be connected to a pipette head of an automated operation device; the hollow cartridge comprises a membrane to achieve a separation of the liquid of the absorbent body unit through the hollow cartridge passage; the membrane is removed by a mechanical force, a pressure, or a vacuum; and the automated operation device is configured to change a position of the pipette head in sequential steps; b) after the fluid biological sample is stored in the absorbent body unit, attaching the absorbent body unit to the distal end of the hollow cartridge; c) aspirating the fluid biological sample into the hollow cartridge through the absorbent body unit; d) temporarily storing the fluid biological sample in the hollow cartridge for up to 600 seconds; e) releasing the fluid biological sample into a first vial or a first well and then again aspirating the fluid biological sample back into the hollow cartridge at least one time in order to achieve a higher concentration of the target analyte compounds of the fluid biological sample in relation to a starting concentration of the target analyte compounds, wherein the fluid biological sample is used as a reconstitution buffer composition for at least one other fluid biological sample in order to achieve the higher target analyte compounds concentration in relation to the starting concentration of the target analyte compounds; f) transferring a predefined volume of the fluid biological sample into a second well or a second vial different than the first well and the first vial; g) removing abundant non-analytical compounds of the fluid biological sample by: adding an internal standard, wherein the internal standard comprises D6-25OH-Vitamin D3, D3-Thiamine diphosphate (TDP), D3-Pyridoxal-5′-phosphate (PLP), [13C,2H7]-apixaban, [13C6]-dabigatran, [13C6]-rivaroxaban, or [2H6]-edoxaban; adding a first set of coated magnetic beads, wherein the first set of coated magnetic beads comprise silica beads coated with a second coating, wherein the second coating comprises one or more functional groups selected from the group consisting of —OH, —COOH, —NH2, R—SO2—OH, —NH2; —RNH, —R2N, CH3, —C2H5, —C4H9, —C8H17, —C9H19, —C10H21, —C11H23, —C12H25, —C13H27, —C14H29, —C15H31, —C16H33, —C17H35, —C18H37, —C6H5, —ZrO2, TiO2, C6H9NO6, phenylhexyl, biphenyl, hydroxyapatite, boronic acid, activated carbon, fullerenes, latex, polyvinyl alcohol, melamine, and chitin; and adding a depletion buffer comprising mixtures of organic solvents and alkaline solutions, wherein the organic solvents or alkaline solutions comprise NaOH, KOH, NH4OH, (NH4)2SO4, (NH4)CH3COO, ZnSO4, MgSO4, K4[Fe(CN)6], CuSO4, AgNO3, NaCl, KCl, MgCl2, (CH3COO)2Pb, FeCl3, HNO3, HClO4, H2SO4, HCl, CF3COOH, CCl3COOH, CH3COOH, CHOOH, wherein the pH-value is in the range of 0 to 14, and wherein an ionic strength between the depletion buffer and the fluid biological sample is between 1 mM and 5000 mM; h) separating the abundant non-analytical compounds of the fluid biological sample by using a magnetic separator; i) receiving the target analyte compounds of the fluid biological sample in the supernatant; j) alternatively binding at least some of the received target analyte compounds from step I) to a second set of coated magnetic beads that are different than the first set of coated magnetic beads and eluting the received target analyte compounds thereafter; and k) analyzing the received target analyte compounds with one or more readout systems used in combination with one or more specific detectors, wherein the readout systems are selected from the group consisting of immunoassays, GC, HPLC, LC, and CE, and the specific detectors are selected from the group consisting of MS/MS, MS, FID, EDC, UV-VIS-spectrometer, IR- spectrometer, fluorescence, and chemiluminescence immunoassay. ### Claim 2 (depends on 1) The method according to claim 1, wherein: the at least one other fluid biological sample is in contact with the reconstitution buffer composition for a period between 1 and 600 seconds; and the reconstitution buffer composition is aspirated into and released from the hollow cartridge by multiple flushing of the reconstitution buffer composition in a multi- directional fashion through the hollow cartridge and absorbent body unit. ### Claim 3 (depends on 1) The method according to claim 1, wherein the reconstitution buffer composition comprises sterile bi-distilled water, and sterile aqueous buffers with a pH range between 0 and 14 and with an ionic strength between 1 mM to 5000 mM. ### Claim 4 (depends on 3) The method according to claim 3, wherein the reconstitution buffer composition comprises salts selected from the group consisting of NaCl, KCl, MgCl2, Na3PO4, Na2HPO4, NaH2PO4, NaHCO3, KHCO3, (NH4)CH3COO, TRIS salts, Na-dodecyl-sulfate and EDTA disodium salt, and EDTA. ### Claim 5 (depends on 4) The method according to claim 4, wherein the reconstitution buffer composition comprises enzymes selected from the group consisting of proteinase K, trypsin, Lys C, lysosyme, lignin, and organic solvents, wherein the organic solvents are selected from the group consisting of methanol, ethanol, isopropanol, n-propanol, acetonitrile, ethylenglycol, polyethylenglycol, THF, DMSO, and DMFA, and wherein the organic/aqueous ratio range is between 0.01%:99.99% and 99.99%:0.01%. ### Claim 6 (depends on 1) The method according to claim 1, wherein the adsorbent body unit comprises a hydrophobic, porous adsorbent material having a predefined volume uptake of the fluid biological sample. ### Claim 7 (depends on 1) The method according to claim 1, wherein the hollow cartridge has a predefined liquid sample volume uptake. ### Claim 8 (depends on 1) The method according to claim 1, wherein the absorbent body unit of the microfluidic device is manufactured from sintered polyethylene and polypropylene material having a pore size ranging from 20 to 100 μm, and wherein the pores are interconnected to each other. ### Claim 9 (depends on 1) The method according to claim 1, wherein the depletion of the abundant non-analytical compounds comprises using a combination of organic solvents and alkaline, acidic and salts solutions in ratios solvents to alkaline, acidic and salts between 0.1%:100% and 100%:0.1%. ### Claim 10 (depends on 1) The method according to claim 1, wherein the target analyte compounds are selected from the group consisting of vitamins, antibiotics, steroids, immunosuppressants, drugs, biomarkers of oxidative stress, amino acids and -thiols, RNA/DNA, enzymes, peptides, drugs, metabolites, biomarkers, and nitrogen compounds for protein adulteration. ### Claim 11 A method to analyze target analyte compounds from a dried biological sample by using a microfluidic sample device comprising a hollow cartridge and an absorbent body unit, the absorbent body unit comprising a filter paper, a capillary pipette tip, or a modified polymeric sintered filter body that is configured to be attached to the hollow cartridge with a pipette-like geometry, the method comprising: a) reconstituting the dried biological sample using a reconstitution buffer composition, wherein: the absorbent body unit comprises one or more single layer structures; different functional groups densities of COOH, NH2, OH, TiO2, and/or ZrO2 are present in each of the one or more single layer structures as a binding tool for a pre-cleaning step; a first coating comprising Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), -ethoxyquin, polyacrylic acid (PAA), polyethyleneimine (PEI), sorbitan esters, polyethoxy sorbitan esters octylphenoxypolyethoxyethanol, Na2- EDTA, Na-citrate, and/or hydrogels is present on each of the one or more single layer structures as artificial antioxidants and as active hydrophilic compounds; the absorbent body unit is positioned at a distal end of the hollow cartridge and a proximal end of the hollow cartridge comprises a passage that is configured to be connected to a pipette head of an automated operation device; the hollow cartridge comprises a membrane to achieve a separation of the liquid of the absorbent body unit through the hollow cartridge passage; the membrane is removed by a mechanical force, a pressure, or a vacuum; the automated operation device is configured to change a position of the pipette head in sequential steps; and the reconstitution buffer composition is dispensed in a first vial or a first well; b) soaking and storing the reconstituted dried biological sample in the absorbent body unit; c) after the reconstituted dried biological sample is stored in the absorbent body unit, attaching the absorbent body unit to the distal end of the hollow cartridge; d) aspirating the reconstituted dried biological sample into the hollow cartridge through the absorbent body unit using a predefined amount of the reconstitution buffer composition; e) temporarily storing the reconstituted dried biological sample in the hollow cartridge for up to 600 seconds; f) releasing the reconstituted dried biological sample back into the first vial or the first well and then again aspirating the reconstituted dried biological sample back into the hollow cartridge at least one time in order to achieve a higher concentration of the target analyte compounds of the reconstituted dried biological sample in relation to a starting concentration of the target analyte compounds, wherein the reconstituted dried biological sample is used as a reconstitution buffer composition for at least one other reconstituted dried biological sample in order to achieve a higher target analyte compounds concentration in relation to the starting concentration of the target analyte compounds; g) transferring a predefined volume of the reconstituted dried biological sample to a second vial or a second well; h) removing abundant non-analytical compounds of the reconstituted dried biological sample by: adding an internal standard, wherein the internal standard comprises D6-25OH-Vitamin D3, D3-Thiamine diphosphate (TDP), D3-Pyridoxal-5′-phosphate (PLP), [13C,2H7]-apixaban, [13C6]-dabigatran, [13C6]-rivaroxaban, or [2H6]-edoxaban; adding a first set of coated magnetic beads, wherein the first set of coated magnetic beads comprise silica beads coated with a second coating, wherein the second coating comprises one or more functional groups selected from the group consisting of —OH, —COOH, —NH2, R—SO2—OH, —NH2; —RNH, —R2N, CH3, —C2H5, —C4H9, —C8H17, —C9H19, —C10H21, —C11H23, —C12H25, —C13H27, —C14H29, —C15H31, —C16H33, —C17H35, —C18H37, —C6H5, —ZrO2, TiO2, C6H9NO6, phenylhexyl, biphenyl, hydroxyapatite, boronic acid, activated carbon, fullerenes, latex, polyvinyl alcohol, melamine, and chitin; and adding a depletion buffer comprising mixtures of organic solvents and alkaline solutions, wherein the organic solvents or alkaline solutions comprise NaOH, KOH, NH4OH, (NH4)2SO4, (NH4)CH3COO, ZnSO4, MgSO4, K4[Fe(CN)6], CuSO4, AgNO3, NaCl, KCl, MgCl2, (CH3COO)2Pb, FeCl3, HNO3, HClO4, H2SO4, HCl, CF3COOH, CCl3COOH, CH3COOH, CHOOH, wherein the pH-value is in the range of 0 to 14, and wherein an ionic strength between the depletion buffer and the reconstituted dried biological sample is between 1 mM and 5000 mM; i) separating the abundant non-analytical compounds of the reconstituted dried biological sample by using a magnetic separator; j) receiving the target analyte compounds of the reconstituted dried biological sample in the supernatant; k) alternatively binding at least some of the received target analyte compounds from step j) to a second set of coated magnetic beads that are different than the first set of coated magnetic beads and eluting the received target analyte compounds thereafter; and l) analyzing the received target analyte compounds with one or more readout systems used in combination with one or more specific detectors, wherein the readout systems are selected from the group consisting of immunoassays, GC, HPLC, LC, and CE, and the specific detectors are selected from the group consisting of MS/MS, MS, FID, EDC, UV-VIS-spectrometer, IR- spectrometer, fluorescence, and chemiluminescence immunoassay. ### Claim 12 (depends on 7) The method according to claim 7, wherein: the at least one other reconstituted dried biological sample is in contact with the reconstitution buffer composition for a period between 1 and 600 seconds; and the reconstitution buffer composition is aspirated into and released from the hollow cartridge by multiple flushing of the reconstitution buffer composition in a multi-directional fashion through the hollow cartridge and the absorbent body unit.